Evidence map›Paper›PMID 39604473›Full record

ArticleScientific reports2024

Survival prediction and molecular subtyping of squamous cell lung cancer based on network embedding.

Dingjie Guo, Jing Chen, Yixian Wang, Xin Liu

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Dingjie GuoEpidemiology and Statistics, School of Public Health, Jilin University, Changchun, 130021, Jilin, China.
Jing ChenAcademy for Advanced Interdisciplinary Studies, Northeast Normal University, Changchun, 130024, China.
Yixian WangEpidemiology and Statistics, School of Public Health, Jilin University, Changchun, 130021, Jilin, China.
Xin LiuEpidemiology and Statistics, School of Public Health, Jilin University, Changchun, 130021, Jilin, China. liuxinjlu01@163.com.

Funding

Fundamental Research Funds for the Central Universities No. 2412023QD033
6 · The paper itself

Abstract

Squamous cell lung cancer (SQCLC), which is fatal to humans, is heterogeneous with different genetic and histological features. We used SBMOI, a multi-omics data integration method from previous study, to integrate clinical, gene expression, and somatic mutation data of SQCLC to construct new patient features. Next, random survival forest (RSF) model and SimpleMKL model were constructed to predict the survival of SQCLC patients, and K-means model was constructed to perform molecular subtyping. The results of the RSF model showed that when the dimension of the patient features were 11 × 364 and the hard threshold was 0.2, we obtained the best results, and the AUC value of the 1-year time-dependent ROC curve was 0.706. The SimpleMKL model, constructed using the same patient features, performed exceptionally well, with 1-year, 5-year, and 10-year survival prediction AUC values of 0.944, 0.947 and 0.950, respectively. We used K-means analysis to identify three SQCLC molecular subtypes with significant survival differences. The patient features constructed by SBMOI were used to effectively predict the survival and molecular subtyping of SQCLC patients. In addition, our study further confirmed the effectiveness in multi-omics data integration task and broad applicability of SBMOI.

Indexed as

Carcinoma, Squamous CellLung NeoplasmsBiomarkers, TumorFemaleHumansMaleMiddle AgedMutationPrognosisROC CurveSurvival AnalysisBiomarkers, TumorMolecular subtypingMulti-omics data integrationSquamous cell lung cancerSurvival prediction

Identifiers

PMID39604473
PMCPMC11603150

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.